CD8+ TILs are able to kill tumor cells both directly when presented with neoantigens and indirectly by activating apoptosis-inducing FAS-FASL pathways [50], and differentiate into tissue resident memory T cells when stimulated by IL-15 and TGF-β [51]. Here, CD8A is linked to neoplasm.